INTRODUCTION: While fatigue has been associated with work limitations the combined influence of specific diagnosis and treatment exposures based on medical records on work limitations in breast cancer survivors is currently unknown. Since symptom burden and perceived health can interfere with work, the present study investigated the relationship among these variables and work outcomes. METHODS: Medical chart abstraction, demographic measures, SF 36, the Work Limitations Questionnaire (WLQ) and measures of symptom burden, including hot flushes were obtained in 83 breast cancer survivors a mean of three years post treatment. OLS and poisson regression were used to determine the relationship of these factors to work productivity and work absences. RESULTS: Breast cancer survivors reported a mean reduction in productivity of 3.1% below the healthy worker norm. This amounts to a loss of 2.48 hours of work over two weeks of full time employment. Stages 1 and 2 were related to work limitations. After controlling for stage, fatigue and hot flashes were each associated with work performance losses of 1.6% (p = 0.05) and 2.2% (p < 0.001), respectively. Protective factors included marriage and greater personal earned income. CONCLUSIONS: Fatigue and hot flashes are important factors related to work productivity in breast cancer survivors even at three years post treatment. IMPLICATIONS FOR SURVIVORS: Therapy for hot flashes should be given serious consideration in breast cancer survivors who are experiencing work limitations.
INTRODUCTION: While fatigue has been associated with work limitations the combined influence of specific diagnosis and treatment exposures based on medical records on work limitations in breast cancer survivors is currently unknown. Since symptom burden and perceived health can interfere with work, the present study investigated the relationship among these variables and work outcomes. METHODS: Medical chart abstraction, demographic measures, SF 36, the Work Limitations Questionnaire (WLQ) and measures of symptom burden, including hot flushes were obtained in 83 breast cancer survivors a mean of three years post treatment. OLS and poisson regression were used to determine the relationship of these factors to work productivity and work absences. RESULTS:Breast cancer survivors reported a mean reduction in productivity of 3.1% below the healthy worker norm. This amounts to a loss of 2.48 hours of work over two weeks of full time employment. Stages 1 and 2 were related to work limitations. After controlling for stage, fatigue and hot flashes were each associated with work performance losses of 1.6% (p = 0.05) and 2.2% (p < 0.001), respectively. Protective factors included marriage and greater personal earned income. CONCLUSIONS:Fatigue and hot flashes are important factors related to work productivity in breast cancer survivors even at three years post treatment. IMPLICATIONS FOR SURVIVORS: Therapy for hot flashes should be given serious consideration in breast cancer survivors who are experiencing work limitations.
Authors: Tim A Ahles; Andrew J Saykin; Charlotte T Furstenberg; Bernard Cole; Leila A Mott; Karen Skalla; Marie B Whedon; Sarah Bivens; Tara Mitchell; E Robert Greenberg; Peter M Silberfarb Journal: J Clin Oncol Date: 2002-01-15 Impact factor: 44.544
Authors: Kishan J Pandya; Gary R Morrow; Joseph A Roscoe; Hongwei Zhao; Jane T Hickok; Eduardo Pajon; Thomas J Sweeney; Tarit K Banerjee; Patrick J Flynn Journal: Lancet Date: 2005 Sep 3-9 Impact factor: 79.321
Authors: Mark S Kaplan; Jean-Marie Berthelot; David Feeny; Bentson H McFarland; Saeeda Khan; Heather Orpana Journal: Qual Life Res Date: 2007-11 Impact factor: 4.147
Authors: Nadine Tchen; Helen G Juffs; Fiona P Downie; Qi-Long Yi; Hanxian Hu; Irene Chemerynsky; Mark Clemons; Michael Crump; Paul E Goss; David Warr; Mary E Tweedale; Ian F Tannock Journal: J Clin Oncol Date: 2003-11-15 Impact factor: 44.544
Authors: David A Adler; Thomas J McLaughlin; William H Rogers; Hong Chang; Leueen Lapitsky; Debra Lerner Journal: Am J Psychiatry Date: 2006-09 Impact factor: 18.112
Authors: Sietske J Tamminga; Jos H A M Verbeek; Monique H W Frings-Dresen; Angela G E M De Boer Journal: Qual Life Res Date: 2013-07-27 Impact factor: 4.147
Authors: Jill E Lavigne; Charles Heckler; Jennifer L Mathews; Oxana Palesh; Jeffrey J Kirshner; Raymond Lord; Andrew Jacobs; Eric Amos; Gary R Morrow; Karen Mustian Journal: Breast Cancer Res Treat Date: 2012-10-02 Impact factor: 4.872
Authors: Li Wang; Brian Y Hong; Sean A Kennedy; Yaping Chang; Chris J Hong; Samantha Craigie; Henry Y Kwon; Beatriz Romerosa; Rachel J Couban; Susan Reid; James S Khan; Michael McGillion; Victoria Blinder; Jason W Busse Journal: J Clin Oncol Date: 2018-05-14 Impact factor: 44.544
Authors: Floortje K Ploos van Amstel; Sanne W van den Berg; Hanneke W M van Laarhoven; Marieke F M Gielissen; Judith B Prins; Petronella B Ottevanger Journal: Support Care Cancer Date: 2013-03-01 Impact factor: 3.603
Authors: Sietske J Tamminga; Angela G E M de Boer; Jos H A M Verbeek; Taina Taskila; Monique H W Frings-Dresen Journal: BMC Cancer Date: 2010-07-01 Impact factor: 4.430
Authors: Hao-Yuan Chang; Aparna C Jotwani; Yeur-Hur Lai; Mark P Jensen; Karen L Syrjala; Jesse R Fann; Julie Gralow Journal: Breast Date: 2016-04-08 Impact factor: 4.380
Authors: Alan Carlotto; Virginia L Hogsett; Elyse M Maiorini; Janet G Razulis; Stephen T Sonis Journal: Pharmacoeconomics Date: 2013-09 Impact factor: 4.981